PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-131743 | Others
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Production of viral vectors, non viral vectors and gene therapy Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET
7.1 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PRODUCTION OF VIRAL VECTORS, NON VIRAL VECTORS AND GENE THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Eurogentec
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 MolMed
16.3 bluebird bio
16.4 Cobra Biologics
16.5 Novasep
16.6 Lonza
16.7 UniQure
16.8 Richter-Helm
16.9 VGXI
16.10 MassBiologics
16.11 PlasmidFactory
16.12 BioReliance
16.13 FUJIFILM Diosynth Biotechnologies
16.14 Aldevron
16.15 Thermo Fisher Scientific (Brammer Bio)
16.16 Vigene Biosciences
16.17 Oxford BioMedica
16.18 Biovian
16.19 Cell and Gene Therapy Catapult
16.20 Spark Therapeutics
16.21 FinVector
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types CoveredAAV
adenovirus
Lentivirus
Retrovirus
Other vectors
plasmid DNA
Major Downstream Industry Covered
cancer
other
viral infection
Hereditary diseases
Companies
Eurogentec
MolMed
bluebird bio
Cobra Biologics
Novasep
Lonza
UniQure
Richter-Helm
VGXI
MassBiologics
PlasmidFactory
BioReliance
FUJIFILM Diosynth Biotechnologies
Aldevron
Thermo Fisher Scientific (Brammer Bio)
Vigene Biosciences
Oxford BioMedica
Biovian
Cell and Gene Therapy Catapult
Spark Therapeutics
FinVector
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.